Skip to main content
. 2020 Oct 13;4(1):e1294. doi: 10.1002/cnr2.1294

FIGURE 1.

FIGURE 1

Kaplan–Meier survival curve of the patients treated by sorafenib with or without TACE. The 3‐month, 6‐month, 1‐year and 2‐year survival rates were 64.7%, 41.2%, 11.8% and 0% for the patients treated by sorafenib without TACE and 85.2%, 70.4%, 44.4% and 14.8% for the patients treated by sorafenib with TACE, respectively (P = .013)